Pharma Tech

Lunit and Summit to evaluate pathology platform for tumour analysis

Oct 26, 2026, 10:00 AM

Read Full Article → Lunit and Summit to evaluate pathology platform for tumour analysis

Translate article text

Choose a language and wait for the translated text.

Lunit and Summit Therapeutics have entered a research agreement to assess the Lunit SCOPE IO AI pathology platform for analysing the tumour microenvironment across immuno-oncology programmes evaluating ivonescimab.